Change Language:
As a component of the DKK 16 billion ($2. 29 billion) investment, Novo Nordisk is expanding the capacity of the production site by expanding the existing quality laboratory, adding aseptic production and completing production processes.
The company anticipates that this will create more than 500 new jobs once the structure is complete. According to the press release, the investment includes more capacity for GLP-1, such as Novo’s Ozempic (semaglutide).
Novo Nordisk first introduced the GLP-1 remedy Semaglutide in the United States in December 2017, under the logo called Ozempic. The drug has since been approved in the U. S. , Canada, the EU, Japan and Australia as a remedy for type 2 diabetes. Subsequently, Novo Nordisk introduced the remedy called Wegovy for the remedy of weight loss, as well as nutrition and physical activity.
Novo Nordisk is the market leader in weight loss control. The company’s weight-loss drugs, Wegovy and Saxenda (liraglutide), generated DKK 30. 4 billion in combined global sales in the first months of 2023, according to Novo Nordisk’s third-quarter monetary report.
Your email will arrive shortly
Weight-loss treatments have regained attention this month after the U. S. Food and Drug Administration released a new warning that the U. S. Food and Drug Administration (FDA) announced that the U. S. Food and Drug Administration had issued a new warning to the U. S. Food and Drug Administration. According to GlobalData’s Pharma Intelligence Center, Zepbound is expected to generate $27. 3 billion in sales through 2029.
GlobalData is the parent company of Pharmaceutical Technology.
News of the expansion comes after it was reported last year that Wegovy was facing origin issues, after contract syringe filler manufacturer Catalent halted deliveries. Catalent won an FDA sanction following the inspection of its Belgian filling plant in October 2021.
In the announcement accompanying the expansion, Novo Nordisk’s executive vice president of product sourcing, quality and IT, Henrik Wulff, said, “The new facility will more than double the size of the site. The facility will be designed as a multi-product facility. to adapt to existing and long-term processes and show the generation and operating environment. As a scalable and cost-effective facility, the structure will focus on delivering the highest quality to patients around the world, in an efficient and environmentally friendly manner.
The product is expected to be completed by 2028.
Check out all newsletters from the GlobalData Media network.